StockNews.AI
MIRA
StockNews.AI
118 days

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

1. MIRA completed IVRT for Ketamir-2 targeting pain-related conditions. 2. The development could enhance MIRA's position in the pharmaceutical market.

2m saved
Insight
Article

FAQ

Why Bullish?

Successful IVRT completion for Ketamir-2 suggests potential market viability, similar to other compounds like Paracetamol which boosted company valuations post-testing.

How important is it?

The achievement in developing a topical formulation could catalyze further investment interest and validate MIRA's research strategy.

Why Long Term?

The implications of IVRT results may take time to translate into market success, akin to earlier stages in drug development cycles.

Related Companies

VRTXREGNAMGN
MIAMI, FLORIDA / ACCESS Newswire / April 23, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), or MIRA, a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic and neuropsychiatric disorders, today announced the completion of in vitro release testing (IVRT) for its topical formulation of Ketamir-2. The formulation is under investigation for localized application in pain-related conditions.

Related News